Refana

News

  • Home
  • Programs
    • AI in Medicine
    • Vaccines
    • Early Cancer Detection
  • Corporate
  • Team
  • About
  • Blog
    • News
    • COVID Industry Updates

12/26/2020

How the Sinovac Vaccine Works

0 Comments

Read Now
 
Picture
The private Chinese company Sinovac developed a coronavirus vaccine called CoronaVac. The government of Turkey announced that a trial there showed the vaccine has an efficacy of 91.25%. But Sinovac has yet to share the full details of its research.

A Vaccine Made From Coronaviruses
CoronaVac works by teaching the immune system to make antibodies against the SARS-CoV-2 coronavirus. The antibodies attach to viral proteins, such as the so-called spike proteins that stud its surface.

​To create CoronaVac, the Sinovac researchers started by obtaining samples of the coronavirus from patients in China, Britain, Italy, Spain and Switzerland. One sample from China eventually served as the basis for the vaccine.

Killing the Virus
The researchers grew large stocks of the coronavirus in monkey kidney cells. Then they doused the viruses with a chemical called beta-propiolactone. The compound disabled the coronaviruses by bonding to their genes. The inactivated coronaviruses could no longer replicate. But their proteins, including spike, remained intact.

The researchers then drew off the inactivated viruses and mixed them with a tiny amount of an aluminum-based compound called an adjuvant. Adjuvants stimulate the immune system to boost its response to a vaccine. 

Inactivated viruses have been used for over a century. Jonas Salk used them to create his polio vaccine in the 1950s, and they’re the bases for vaccines against other diseases including rabies and hepatitis A.

​Prompting an Immune Response
Because the coronaviruses in CoronaVac are dead, they can be injected into the arm without causing Covid-19. Once inside the body, some of the inactivated viruses are swallowed up by a type of immune cell called an antigen-presenting cell.
​
​Read the full article

By Jonathan Corum and Carl Zimmer​

Back to Blog

Share

0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

Details

    Categories

    All
    Artificial Intelligence
    Blood Testing
    Covid 19
    Early Cancer Detection
    Press Release

    Archives

    January 2023
    November 2022
    September 2022
    July 2022
    May 2022
    April 2022
    March 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    July 2020
    June 2020

    RSS Feed

​Practical Solutions for complex and ​urgent global medical problems

HOME     |     PROGRAMS    |    TEAM     |     ABOUT     |     NEWS
Privacy Policy | Cookie Policy
© 2023 Refana Inc
  • Home
  • Programs
    • AI in Medicine
    • Vaccines
    • Early Cancer Detection
  • Corporate
  • Team
  • About
  • Blog
    • News
    • COVID Industry Updates